This explanation is consistent with a previous report showing a sustained increase in hematocrit in patients with type 2 diabetes treated with dapagliflozin who were also receiving chronic treatment with insulin (Aberle et al., 2020). The gene discussed is INS; the disease is type 2 diabetes mellitus.